79098-98-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Tert-butyl 4-(2-aminobenzylamino)piperidine-1-carboxylate serves as a valuable building block in the synthesis of biologically active compounds. Its unique structure allows for the creation of new drugs targeting a range of conditions, including neurological disorders, cancer, and infectious diseases.
Used in the Development of Neurological Disorder Treatments:
In the pharmaceutical industry, tert-butyl 4-(2-aminobenzylamino)piperidine-1-carboxylate is utilized as a key component in the development of treatments for neurological disorders. Its structure enables the design of molecules that can modulate neurotransmitter systems and target specific receptors, offering potential therapeutic benefits for patients suffering from such conditions.
Used in Cancer Therapy:
Tert-butyl 4-(2-aminobenzylamino)piperidine-1-carboxylate is employed as a precursor in the synthesis of anticancer agents. Its chemical properties allow for the creation of molecules that can inhibit the growth and proliferation of cancer cells, making it a promising candidate for the development of novel cancer therapies.
Used in Infectious Disease Treatment:
In the field of infectious diseases, tert-butyl 4-(2-aminobenzylamino)piperidine-1-carboxylate is used as a starting material for the synthesis of compounds with antiviral, antibacterial, or antifungal properties. Its versatile structure enables the design of molecules that can target specific pathogens and disrupt their replication or survival mechanisms, offering new treatment options for various infectious diseases.

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 4403-69-4 2-amino-1-benzylamine 
• 552-89-6 2-nitro-benzaldehyde 
• 87120-79-4 tert-butyl 4-((2-nitrobenzyl)amino)piperidine-1-carboxylate 

Downstream Products

• 960221-97-0 tert-butyl 4-(2-oxo-1,2,3,4-tetrahydroquinazolin-3-yl)piperidine-1-carboxylate 
• 79106-65-3 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-oxo-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-71-1 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-67-5 3-{1-[2-Oxo-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-66-4 3-{1-[2-(3,4-Dimethoxy-phenyl)-1-methyl-2-oxo-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-73-3 3-{1-[2-Hydroxy-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-72-2 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-1-methyl-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-68-6 3-{1-[1-Methyl-2-oxo-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79122-28-4 3-{1-[2-Hydroxy-1-methyl-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79098-75-2 3-piperidin-4-yl-3,4-dihydro-1H-quinazoline-2-one 

Relevant academic research and scientific papers

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

An efficient synthesis of the piperidinyl dihydroquinazolinone (PDQ) fragment of olcegepant

Olcegepant is one of the most potent and selective small molecule CGRP antagonists for the treatment of migraine headaches. Herein, we describe a new and efficient synthesis of the key piperidinyl dihydroquinazolinone (PDQ) fragment of olcegepant. PDQ plays a key role in the activity of CGRP antagonists. Primary improvements over existing methods include a high-yielding reductive amination step, greater overall yield, and operational simplicity. Coupling of PDQ to a D-tyrosine derivative effectively produced over one half of the total molecular structure of olcegepant. A unique tandem deprotection-nucleophilic addition sequence was also applied to the coupling of Fmoc-PDQ with phenyl isocyanate.

CGRP receptor antagonists

The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.

AMIDE-SUBSTITUTED ARYL PIPERIDINES

Amide-substituted aryl piperidines derivatives of the following Formulas are provided:(Formulas), in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache, such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.

BIARYL KETONE-SUBSTITUTED PIPERIDINES

Biaryl ketone-substituted piperidines of the following Formulas are provided:, and in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.

Synthesis of (1-substituted piperidin-4-yl)-1H-benzimidazoles and (1-substituted piperidin-4-yl)-3,4-dihydroquinazolines as possible antihypertensive agents

Structural modifications of 4-piperidylbenzimidazolinones (I) by replacing the benzimidazolinone group with other heterocycles (2-cyanoamino, 2-ethoxy, and 2-methylbenzimidazole and 2-cyanoamino-3,4-dihydroquinazoline) has been made and a number of new pi